Navigation Links
RiboMed Receives Three Additional Patents for Disease Diagnostics Methods
Date:12/5/2012

CARLSBAD, CA (PRWEB) December 05, 2012

“These patent issuances further solidify RiboMed’s position in clinical diagnostics, particularly in the use of DNA Methylation biomarkers for cancer detection, staging and drug development” stated Dr. Michelle Hanna, Chief Executive Officer and Scientific Director of RiboMed. “The technologies protected by these patents make sensitive, reproducible and quantitative DNA methylation profiling possible even on formalin fixed paraffin embedded (FFPE) tumor tissues, as we have shown with the G-CIMP DecisionDx test launched in RiboMed’s CLIA laboratory earlier this year.” G-CIMP stands for Glioma specific CpG Island Methylator Phenotype, and the test predicts the aggressiveness of certain brain tumors, providing physicians and patients with a new tool for making treatment decisions. The test was developed in partnership with Castle Biosciences.

The claims of U.S. Patent 8,263,339, entitled “Abscription based molecular detection” broadly cover RiboMed’s core Abscription technology for use in detecting a wide variety of molecular biomarkers, including DNA, RNA, protein and methylated DNA. Detection tests reduced to practice in addition to those for DNA methylation include sensitive and robust assays for Salmonella (DNA), viral RNAs and protein toxins, such as ricin, Botulinum toxin and the food poisoning agent, SEB. These assays were developed together with the Departments of Defense (DARPA) and Homeland Security (HSARPA).

U.S. Patent 8,242,243, entitled “Methods and reagents for detecting CpG methylation with a methyl CpG binding protein (MBP)” covers a highly quantitative and sensitive, bisulfite-free method for measuring DNA methylation at CpG sites and CpG islands using RiboMed’s proprietary Methyl CpG binding fusion protein. This work was supported in part by Small Business Innovative Research grant and contract awards from the National Cancer Institute. In addition to the currently available brain cancer staging test, RiboMed is developing similar DNA methylation profile based diagnostic, prognostic and companion diagnostic tests for ovarian and lung cancers.

Finally, U.S. Patent 8,211,644, entitled “Molecular beacon based methods for detection of targets using Abscription” provides claims to sensitive fluorescence-based methods using molecular beacons to detect the products of Abscription and makes real time detection methods possible. The molecular beacon-based technology makes Abscription more attractive to the vast majority of clinical and research laboratories that do not have access to a mass spectrometer, which is used for the current G-CIMP assay, but routinely use fluorescence detection instruments. The molecular beacon format allows for more streamlined workflows and faster assay set-up. The new fluorescence read-out is readily adapted for the detection of RNA, DNA and protein targets and should have wide applicability in areas such as cancer diagnostics and environmental testing.

About RiboMed Biotechnologies, Inc.
RiboMed Biotechnologies, Inc. (http://www.ribomed.com) is a molecular diagnostic company providing proprietary epigenetic and genetic biomarker tests for applications in Personalized Medicine and Companion Diagnostics, which is the use of information about an individual’s cellular biomarkers to detect and treat disease. The current focus of the Company is on the detection of epigenetic biomarkers (DNA methylation) and genetic biomarkers associated with disease initiation, progression and response to drug treatment.

RiboMed provides products and services for disease management and drug development utilizing its proprietary and patented technologies for biomarker detection (Abscription®) and methylated DNA isolation and quantification (MethylMagnet® and MethylMeter®). In February, 2011, the Company expanded to add the RiboMed Clinical Services Laboratory (RCSL, CLIA License #05D2020043).

For more information, contact:
    Michelle Hanna, Ph.D.
    CEO & Scientific Director
    760-448-1355
    mmhanna(at)ribomed(dot)com

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of RiboMed and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the Company’s control, and may turn out to be materially different. RiboMed expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.

Read the full story at http://www.prweb.com/releases/2012/12/prweb10199227.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. BioNeutral Group Receives Positive Testing Results From A Global Independent Laboratory For Its Ygiene Sterilant Against Anthrax Spores
2. iBio, Inc. Receives Notice from NYSE MKT Staff that Company Currently is Below Certain Continued Listing Standards
3. AtheroNova Receives Notice of Issuance of Its U.S. Patent 8,304,383
4. Ceres Receives $3.5 million from USAID for Trait Stacks
5. Creabilis Receives Prestigious Technology Strategy Board Biomedical Catalyst Award
6. Hertz Fellow, Grant I. Gillary, Receives Hertz Foundation-George Lerman Fellowship
7. Sinovac Biotech Receives GMP Certification for Mumps Vaccine Production Facility
8. Lifeline Biotechnologies Receives Patent for Methods to Collect and Analyze Breast Thermal Data to Determine Suspect Conditions
9. Northwest Bio Receives Regulatory Approval To Proceed With Its Phase III Trial In The UK
10. Rosetta Genomics Receives 2012 North American Entrepreneurial Company of the Year Award by Frost & Sullivan
11. Perrigo Receives FDA Approval And Commences Launch Of Morphine Sulfate 100ml/5% Oral Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... Seattle, WA (PRWEB) , ... ... ... the industry leader in Hi-C-based genomic technologies, launched its ProxiMeta™ Hi-C metagenome ... the ProxiMeta Hi-C kit and accompanying cloud-based bioinformatics software to perform Hi-C ...
(Date:10/6/2017)... Boston, Mass. (PRWEB) , ... October 06, 2017 ... ... spotlight female entrepreneurship within the healthcare and technology sector at their fourth annual ... six panels featuring 30 inspiring speakers and the ELEVATE pitch competition showcasing early ...
(Date:10/5/2017)... LINDA, CA (PRWEB) , ... October 05, 2017 , ... ... innovators, engineers, and scientists from around the world, is giving back to cancer research ... sold in October. , Now through October 31, shoppers can use promo code ...
(Date:10/5/2017)... ... October 05, 2017 , ... ... applications of its Nanobind DNA/RNA extraction technology . Nanobind is a novel ... the surface and that can be used for a wide variety of sample ...
Breaking Biology Technology:
(Date:6/14/2017)... June 15, 2017  IBM (NYSE: IBM ) is introducing ... event dedicated to developing collaboration between startups and global businesses, ... 15-17. During the event, nine startups will showcase the solutions ... various industries. France ... market, with a 30 percent increase in the number of ...
(Date:5/16/2017)... DALLAS , May 16, 2017   ... for health organizations, and MD EMR Systems ... certified development partner for GE, have established a ... Patient Portal product and the GE Centricity™ products, ... Centricity EMR. These new integrations ...
(Date:4/19/2017)... York , April 19, 2017 ... as its vendor landscape is marked by the presence ... market is however held by five major players - ... Together these companies accounted for nearly 61% of the ... the leading companies in the global military biometrics market ...
Breaking Biology News(10 mins):